Results 71 to 80 of about 622,843 (190)

Therapeutics Letter 121

open access: yes, 2019
Therapeutics Letter 121 is the first of two issues celebrating 25 years of The Therapeutics Initiative by highlighting key conclusions from the 120 issues of the Therapeutics Letter that have been published to date.Medicine, Faculty ofAnesthesiology ...
Therapeutics Initiative (University of British Columbia)
core   +1 more source

Early diagnosis of axial spondyloarthritis is associated with less long‐term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management in rheumatic diseases registry

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration ≤2 years of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between early and established axSpA patients treated with biologic/targeted synthetic disease‐modifying anti ...
Annik Steimer   +18 more
wiley   +1 more source

Medical Pharmacology and Therapeutics

open access: yes, 2001
This text covers the whole gamut of pharmacology from basic science pharmacology and pathophysiology, through clinical pharmacology to therapeutics. This integrative approach is in line with the medical curricula.
Hillier, Keith   +2 more
core   +1 more source

Anodal Transcranial Direct Current Stimulation Improves Social Behavior Alongside Neuroplastic Changes in a Tsc2+/− Rat Model of Autism Spectrum Disorder

open access: yesAutism Research, EarlyView.
ABSTRACT Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by altered synaptic connectivity and network organization, resulting in profound impairments in social communication and interaction. Transcranial direct current stimulation (tDCS) represents a promising approach to modulate maladaptive plasticity associated with ASD;
Antonia Ramme   +9 more
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort   +8 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver

open access: yesHepatology, EarlyView., 2022
Hepatic endothelial Alk1 signaling protects from development of vascular malformations while maintaining organ‐specific endothelial differentiation and angiocrine portmanteau of the names Wingless and Int‐1 signaling. Abstract Background and Aims In hereditary hemorrhagic telangiectasia (HHT), severe liver vascular malformations are associated with ...
Christian David Schmid   +20 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis   +4 more
wiley   +1 more source

Therapeutics Letter 127

open access: yes, 2020
Therapeutics Letter 127 discusses personal prescribing portraits as an innovative method for community-based physicians to monitor and evaluate the appropriateness of their prescribing practices.Medicine, Faculty ofAnesthesiology, Pharmacology and ...
Therapeutics Initiative (University of British Columbia)
core   +1 more source

Home - About - Disclaimer - Privacy